Lilly trial slowdown could include Phase III GI candidate; Syncona among others acknowledging delays

Lilly’s decision to delay most clinical trial starts and suspend enrollment in most ongoing trials makes it the latest and largest biopharma to acknowledge a broad impact of the COVID-19 outbreak on its development plans for therapeutic candidates.

The decision won’t affect most of the late-stage trials in

Read the full 470 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE